Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Variegate Porphyria (VP)

Inclusion Criteria: * Male or female patients with confirmed diagnosis of VP. * Patients with VP-related skin symptoms. * Aged 18-70 years. Exclusion Criteria: * Allergy to afamelanotide or polymer or to local anaesthetic to be used if applicable. * Had two or more acute attacks of hepatic porphyria, as defined by the occurrence or acute porphyric symptoms within 12 months prior to the Screening period. * Individual history of malignant or premalignant skin lesions. * Individual or family history of melanoma. * Presence of severe hepatic disease. * Renal impairment. * Female who is pregnant or lactating. * Females of child-bearing potential not using adequate contraceptive or a life-style excluding pregnancy. * Sexually active man with a partner of child-bearing potential not using adequate contraceptive measures. * Use of any other prior and concomitant therapy which may interfere with the objective of the study, within 30 days prior to the Screening period. * Participation in a clinical trial within 30 days prior to the Screening period.